NRX Pharmaceuticals, Inc. (NRXP)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 400K 800K 1.2M Q3 '24: 0 Q4 '24: 0 Q1 '25: 0 Q2 '25: 0 Q3 '25: 242K Q4 '25: 983K Q1 '26: 1.1M Q2 '26: 1.1M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Gross Profit Quarterly

0 200K 400K 600K Q3 '24: 0 Q4 '24: 0 Q1 '25: 0 Q2 '25: 0 Q3 '25: 145K Q4 '25: 575K Q1 '26: 437K Q2 '26: 426K Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-60M -40M -20M 0 20M 40M 60M Q3 '21: -20.1M Q4 '21: -53M Q1 '22: -15.7M Q2 '22: -9.6M Q3 '22: -9.1M Q4 '22: -9.9M Q1 '23: -3.8M Q2 '23: -8.2M Q3 '23: -5.8M Q4 '23: -4.4M Q1 '24: -6M Q2 '24: -7M Q3 '24: -3M Q4 '24: -2.4M Q1 '25: -3.8M Q2 '25: -3.7M Q3 '25: -4M Q4 '25: -4.6M Q1 '26: -4.7M Q2 '26: -6.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '21: -37M Q4 '21: -30.4M Q1 '22: -13.4M Q2 '22: -7M Q3 '22: -9.1M Q4 '22: -10.2M Q1 '23: -5.5M Q2 '23: -8.7M Q3 '23: -6.1M Q4 '23: -4.3M Q1 '24: -6.5M Q2 '24: -7.9M Q3 '24: -1.6M Q4 '24: -9.1M Q1 '25: -5.5M Q2 '25: -17.6M Q3 '25: -5.9M Q4 '25: 360K Q1 '26: -1.4M Q2 '26: -16.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 250K 500K 750K Q3 '24: 0 Q4 '24: 0 Q1 '25: 0 Q2 '25: 0 Q3 '25: 97K Q4 '25: 408K Q1 '26: 631K Q2 '26: 675K Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating Cash Flow Quarterly

-18M -12M -6M 0 6M 12M 18M Q3 '21: -12M Q4 '21: -11.3M Q1 '22: -10.4M Q2 '22: -14.8M Q3 '22: -6.3M Q4 '22: -8.3M Q1 '23: -6.1M Q2 '23: -7.8M Q3 '23: -4.6M Q4 '23: -3.2M Q1 '24: -3.7M Q2 '24: -2.6M Q3 '24: -2.3M Q4 '24: -2.1M Q1 '25: -3.5M Q2 '25: -4M Q3 '25: -2.9M Q4 '25: -3.7M Q1 '26: -4.3M Q2 '26: -8.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-18M -12M -6M 0 6M 12M 18M Q3 '21: -12M Q4 '21: -11.3M Q1 '22: -10.4M Q2 '22: -14.8M Q3 '22: -6.3M Q1 '23: -6.1M Q2 '23: -7.8M Q3 '23: -4.6M Q4 '23: -3.2M Q1 '24: -3.7M Q2 '24: -2.6M Q3 '24: -2.3M Q4 '24: -2.1M Q1 '25: -3.5M Q4 '21 Q2 '22 Q1 '23 Q3 '23 Q1 '24 Q3 '24 Q1 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 30M 60M 90M Q2 '20: 36.7M Q3 '20: 34.1M Q1 '21: 35.7M Q2 '21: 42.5M Q3 '21: 51.7M Q1 '22: 63.7M Q2 '22: 65.7M Q3 '22: 66.4M Q1 '23: 6.6M Q2 '23: 73.2M Q3 '23: 81.9M Q1 '24: 8.9M Q2 '24: 10.5M Q3 '24: 11M Q1 '25: 16.4M Q2 '25: 17.9M Q3 '25: 22.2M Q1 '26: 32.3M Q2 '26: 37.6M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-2.70 -1.80 -0.90 0.00 0.90 1.80 2.70 Q3 '19: -0.20 Q4 '19: -0.12 Q1 '20: 0.01 Q2 '22: -1.57 Q3 '22: -0.99 Q4 '22: -0.61 Q1 '23: -2.06 Q2 '23: -2.07 Q3 '23: -2.00 Q4 '23: -2.35 Q1 '24: -1.43 Q2 '24: -2.06 Q3 '24: -2.14 Q4 '24: -2.41 Q1 '25: -2.01 Q2 '25: -2.24 Q3 '25: -2.36 Q4 '25: -1.34 Q1 '26: -1.04 Q2 '26: -0.50 Q4 '19 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.